<DOC>
	<DOCNO>NCT01674166</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics single oral dose 0.03 mg/kg prucalopride paediatric subject age &gt; = 4 &lt; = 12 year functional faecal retention . Hypothesis : Pharmacokinetic profile prucalopride paediatric subject expect resemble adult pharmacokinetic profile</brief_summary>
	<brief_title>Single Dose Pharmacokinetics Prucalopride Paediatric Subjects , With Functional Faecal Retention</brief_title>
	<detailed_description>This multicentre , open-label , single-dose pharmacokinetic trial . A minimum 24 paediatric subject ( age ≥ 4 ≤ 12 year ) functional faecal retention ( FFR ) administer single dose prucalopride oral solution . All subject qualify enter trial receive single dose 0.03 mg/kg prucalopride oral solution Hour 0 Day 1 . One blood sample drawn prior dose , 13 sample draw 72-hour interval follow single dose prucalopride . Urine collect quantitatively first 24 hour . Plasma prepare blood sample urine sample assay prucalopride concentration . Safety monitor 72-hour interval follow dose trial medication .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Subjects confirm diagnosis FFR , define minimum 2month history faecal impaction , plus least one following : &lt; 3 bowel movement per week toilet ; A history soiling ; Male female subject ≥ 4 ≤ 12 year age , Tanner stage 1 2 less ; Weightheight proportionality age within 5th 95th percentile ; Written inform consent , sign subject 's legal guardian investigator , ; Subject assent document form notetofile subject 's source documentation . Requirement medication period trial ; Evidence examination laboratory test abnormal growth ; An abnormal neurologic examination ; Cystic fibrosis ; History , current anorectal malformation ; Diagnosed chromosomal abnormality ( e.g. , Down 's Syndrome ) ; Disease state surgery know significantly affect gastrointestinal absorption drug , assessment trial drug 's effect ; Any history , clinical and/or biochemical evidence clinically significant renal liver disease cirrhosis ; Clinically significant anaemia ; Use investigational drug within 4week period prior administration trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>